Oncotherapeutic Protein Kinase Inhibitors Associated With Pro-Arrhythmic Liability.

ABSTRACT:

Background

Ibrutinib is a protein kinase inhibitor that has been widely successful in treating multiple common variations of B-cell cancers. However, an unfortunate side effect of ibrutinib is that it predisposes patients to development of atrial fibrillation.

Objectives

The purpose of this study was to assess other commonly prescribed protein kinase inhibitors for similar pro-arrhythmic liability.

Methods

This study comprehensively evaluated data from the U.S. Food and Drug Administration adverse events reporting system and determined the reporting of cardiac arrhythmia attributed to kinase inhibitor therapy using a multivariable logistic regression model. We evaluated 3,663,300 case reports containing 23,067 cases of atrial fibrillation and 66,262 cases of cardiac a

SUBMITTER: Ye JZ 

PROVIDER: S-EPMC8352262 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature